Advanced Solid Tumors Clinical Trials in Orlando, Florida

8 studies are recruiting for advanced solid tumors in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Florida Cancer Specialists North / Sarah Cannon Research Institute, Orlando, Florida

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

2. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

   This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) - Lake Nona, Orlando, Florida

   Locations

   17 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06792552 on ClinicalTrials.gov

3. Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

   This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06384352 on ClinicalTrials.gov

4. A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

   This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists, Orlando, Florida

   Locations

   5 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT07372625 on ClinicalTrials.gov

5. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

   The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Orlando Health UF Health Cancer Center, Orlando, Florida

   Locations

   39 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT05533697 on ClinicalTrials.gov

6. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

   The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Orlando, Florida

   Locations

   12 in total

   Run by

   Alterome Therapeutics, Inc.

   See if you can join NCT06835569 on ClinicalTrials.gov

7. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

   This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The st…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   UCF Lake Nona Cancer Center, Orlando, Florida

   Locations

   38 in total

   Run by

   Shanghai Allink Biotherapeutics Co., Ltd.

   See if you can join NCT06656390 on ClinicalTrials.gov

8. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site 137, Orlando, Florida

   Locations

   107 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05914116 on ClinicalTrials.gov